alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 226–250 of 327 studies in Cognitive tests and assessment · free to read (page 10 of 14) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 327 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

What “Cognitive tests and assessment” covers

Cognitive tests and assessment — Memory and thinking tests, screening tools and rating scales: how well they measure what they claim to.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Prevalence and correlates of the head turning sign in mild cognitive impairment and dementia due to neurodegenerative, chronic cerebrovascular, and mixed etiologies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer s Disease 2025-02-16

In patients with cognitive impairment due to diverse causes, the HTS might occur regardless of MCI versus dementia status and across different etiologies. 4 key findings →

Participants: 121 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Usability and feasibility of INFORMA platform for computerized cognitive stimulation in mild cognitive impairment and early dementia: an 8-week multicenter study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Aging Clinical and Experimental Research 2026-03-13

Of 219 completing participants (mean age 73.5 years), the mean SUS score was 82.0 (95% CI: 80.3-83.8), with 84% exceeding the usability threshold (SUS score > 68). 5 key findings →

Participants: 241 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-12-01

Data collection began in March 2024. So far 562 people completed a pre-screening online questionnaire, with 190 passing pre-screening of whom 54% met eligibility criteria. 5 key findings →

Participants: 24 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neuropsychologia 2005-01-01

Neuropsychiatric symptoms seen in Alzheimer's disease (AD) are not simply a consequence of neurodegeneration, but probably result from differential neurotransmitter alterations, which some patients are more at risk of than others. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brief screening tests for dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Canadian journal of psychiatry. Revue canadienne de psychiatrie 2002-10-01

We selected screening tests that met 2 criteria: 1) administration time of 10 minutes or less in studies including individuals with, and without, dementia; and 2) performance characteristics evaluated in at least 1 community or clinical sample of older adults. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Screening for dementia in primary care: a review of the use, efficacy and quality of measures

✓ Peer-reviewed alzhub usefulness score 44 out of 100. International psychogeriatrics 2008-06-05

Despite evidence that early identification of dementia is of growing policy and practice significance in the U.K., limited work has been done on evaluating screening measures for use in primary care. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The accuracy of the MMSE in detecting cognitive impairment when administered by general practitioners: a prospective observational study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. BMC family practice 2008-05-13

The Mini-Mental State Examination (MMSE) has contributed to detecting cognitive impairment, yet few studies have evaluated its accuracy when used by general practitioners (GP) in an actual public-health setting. 3 key findings →

Participants: 317 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Risk of a Dementia Diagnosis in Community-Dwelling Older Adults With Normal MMSE Scores in the United States

✓ Peer-reviewed alzhub usefulness score 44 out of 100. American Journal of Medicine Open 2026-02-25

• Lower MMSE scores—even by a single point—were independently associated with a significantly higher risk of developing ADRD. • Individuals with MMSE scores between 27 and 30 should not be viewed as a uniform group. • Further studies are needed to find ways to prevent ADRD in people who are at risk but do not yet show symptoms. 5 key findings →

Participants: 1,228 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Deep cervical lymphatic-venous anastomosis in dementia: a clinical and mechanistic evaluation

✓ Peer-reviewed alzhub usefulness score 44 out of 100. International Journal of Surgery 2025-12-17

Within one week after dcLVA, 64.3% of patients demonstrated MMSE improvement, with further functional gains observed in continence, emotional regulation, motor coordination, and feeding independence. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Assessment of localized brain regions correlated with MMSE using VBM analysis of structural MRI in a Japanese sample

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neuroimage Reports 2025-04-28

The global aging population has led to a significant rise in dementia and cognitive decline, with Alzheimer's disease as the primary cause. 5 key findings →

Design: cross-sectional Participants: 510 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Benson Complex Figure Test for the Differential Diagnosis of Dementias

✓ Peer-reviewed alzhub usefulness score 44 out of 100. NeuroSci 2026-03-20

The Benson Complex Figure Test (BCFT) is a neuropsychological tool designed to assess visuospatial construction and visual memory with lower complexity than traditional tests. 4 key findings →

Design: cross-sectional Participants: 1,428 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Serum levels of S100B and NSE proteins in Alzheimer's disease patients

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of neuroinflammation 2010-01-27

Alzheimer's disease is the most common dementia in the elderly, and the potential of peripheral biochemical markers as complementary tools in the neuropsychiatric evaluation of these patients has claimed further attention. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2003-08-01

Previously, we reported that morning bright light therapy improved sleep time and cognitive function in Alzheimer type of dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia classification using two-channel electroencephalography features

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific Reports 2025-04-03

This study aimed to develop a novel classification model using wearable two-channel electroencephalography (EEG) data to differentiate between patients with dementia and normal controls (NCs). 2 key findings →

Participants: 54 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Improved dementia screening for elderly with low education in South Korea using the Cognitive Impairment Screening Test (CIST)

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Neuroscience 2025-05-14

< 0.001) for both measures. When distinguishing NC from MCI/DM, the CIST outperformed the K-MMSE, demonstrating a higher AUC (0.869 vs. 0.842) and F1-score (0.697 vs. 0.409). 3 key findings →

Participants: 100 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events